Podcast
Questions and Answers
What is the primary effect of filgrastim on neutrophils in patients undergoing chemotherapy for AML?
What is the primary effect of filgrastim on neutrophils in patients undergoing chemotherapy for AML?
- It inhibits the division of immature neutrophils.
- It binds to and activates mature neutrophils. (correct)
- It stimulates the production of platelets.
- It enhances the function of T cells.
Which drug is specifically associated with a risk of splenic enlargement or rupture?
Which drug is specifically associated with a risk of splenic enlargement or rupture?
- Sargramostim
- Filgrastim (correct)
- Blinatumomab
- Tisagenlecleucel
What symptom should patients receiving sargramostim immediately report to their healthcare provider?
What symptom should patients receiving sargramostim immediately report to their healthcare provider?
- Dyspnea or palpitations (correct)
- Increased appetite
- Mild headache
- Dizziness upon standing
Which of the following cytokines targets the CD19 protein on T cells and malignant cells in ALL treatment?
Which of the following cytokines targets the CD19 protein on T cells and malignant cells in ALL treatment?
During which type of drug infusion is it essential to monitor for symptoms of cytokine release syndrome?
During which type of drug infusion is it essential to monitor for symptoms of cytokine release syndrome?
What is a significant concern for patients undergoing treatment with blinatumomab?
What is a significant concern for patients undergoing treatment with blinatumomab?
Which of the following monitoring assessments is NOT mentioned for patients receiving filgrastim?
Which of the following monitoring assessments is NOT mentioned for patients receiving filgrastim?
Which drug stimulates the production, division, and differentiation of granulocytes?
Which drug stimulates the production, division, and differentiation of granulocytes?
What symptoms should be monitored for in patients receiving blinatumomab to detect tumor lysis syndrome?
What symptoms should be monitored for in patients receiving blinatumomab to detect tumor lysis syndrome?
Which of the following is a symptom of pancreatitis that patients receiving blinatumomab or interferons should be monitored for?
Which of the following is a symptom of pancreatitis that patients receiving blinatumomab or interferons should be monitored for?
What condition's symptoms should be monitored for in patients receiving interferons?
What condition's symptoms should be monitored for in patients receiving interferons?
What is a primary effect of drug antibody conjugates like inotuzumab and gemtuzumab?
What is a primary effect of drug antibody conjugates like inotuzumab and gemtuzumab?
Which of the following should be monitored as a potential side effect of FLT3 inhibitors like gitertinib?
Which of the following should be monitored as a potential side effect of FLT3 inhibitors like gitertinib?
Which monoclonal antibody binds to the CD52 antigen on B and T cells?
Which monoclonal antibody binds to the CD52 antigen on B and T cells?
What should patients using rituximab immediately report to their healthcare provider?
What should patients using rituximab immediately report to their healthcare provider?
What is a symptom of immune thrombocytopenia that should be monitored in patients receiving alemtuzumab?
What is a symptom of immune thrombocytopenia that should be monitored in patients receiving alemtuzumab?
What symptom should patients receiving obinutuzumab be instructed to notify their healthcare provider about?
What symptom should patients receiving obinutuzumab be instructed to notify their healthcare provider about?
What symptom is associated with potential hepatotoxicity that patients receiving drug antibody conjugates need to monitor?
What symptom is associated with potential hepatotoxicity that patients receiving drug antibody conjugates need to monitor?
What is an important cardiovascular symptom to monitor in patients receiving interferons?
What is an important cardiovascular symptom to monitor in patients receiving interferons?
Which of the following symptoms indicate the need for intervention in patients receiving tisagenlecleucel?
Which of the following symptoms indicate the need for intervention in patients receiving tisagenlecleucel?
What condition should be monitored for symptoms in patients taking interferons for their treatment?
What condition should be monitored for symptoms in patients taking interferons for their treatment?
Flashcards are hidden until you start studying
Study Notes
Colony-Stimulating Factors
- Filgrastim (Granix, Neupogen) stimulates immature neutrophils to divide and differentiate.
- Sargramostim (Leukine) stimulates the production, division, differentiation, and activation of granulocytes.
Cytokines
- Blinatumomab (Blincyto) is a monoclonal antibody that targets the CD19 protein on malignant cells.
- Interferons target the IFNAR1/2 pathway in patients with hairy cell leukemia and Philadelphia chromosome–positive CML.
- Tisagenlecleucel (Kymirah) targets malignant T cells expressing the CD19 protein in patients with ALL.
Drug Antibody Conjugates
- Inotuzumab (Besponsa) attaches to the CD22 antigen on the surface of tumor cells in ALL.
- Gemtuzumab (Mylotarg) attaches to the CD33 antigen to cause cell death in AML.
FLT3 Inhibitors
- Gitertib (Xospata) and Midostaurin (Rydapt) inhibit FLT3 receptor signaling and cell proliferation.
Monoclonal Antibodies
- Alemtuzumab (Campath, Lemtrada) binds to the CD52 antigen on the surface of B and T cells in CLL.
- Obinutuzumab (Gazyva) targets an antigen on the surface of premature and mature B cells in CLL.
- Ofatumumab (Arzerra) also binds to CD20 to cause cell death in CLL.
- Rituximab (Rituxan, Ruxience, Truxima) binds to the CD20 antigen on the surface of lymphoma cells, preventing cell cycle activation and causing cell death in CLL.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
